

WHAT IS CLAIMED IS:

1. A method of minimizing blood reflux from an episcleral vein or reducing pain during eye surgery, comprising:
 - placing a glaucoma implant into an eye of a mammal; and
 - administering a vasoconstrictive agent to the eye to reduce blood flow through the episcleral vein or reduce pain.
2. A method of minimizing blood reflux from an episcleral vein or reducing pain during eye surgery, comprising:
 - advancing an implant from an anterior chamber through trabecular meshwork toward Schlemm's canal; and
 - administering a vasoconstrictive agent to eye tissue to decrease blood flow through the episcleral vein or reduce pain.
3. The method of claim 1, wherein the vasoconstrictive agent is an alpha agonist.
4. The method of claim 1, wherein the administering is topical.
5. The method of claim 2, further comprising administering a second agent to eye tissue.
6. The method of claim 3, wherein the second agent is tetracaine.
7. The method of claim 3, wherein the second agent is brimonidine.
8. The method of claim 1, wherein the vasoconstrictive agent is an eye solution with a pH between 4 and 8.
9. The method of claim 1, wherein the vasoconstrictive agent is an active ingredient in an eye solution at a concentration between 0.01 and 2 weight percent.
10. The method of claim 1, wherein the implant is configured to be placed through the trabecular meshwork such that a proximal terminal of the implant is exposed to the anterior chamber of the eye and a distal terminal is exposed to Schlemm's canal of the eye.
11. A method of enhancing penetration of a poorly absorbing eye medicine, comprising co-administering to the eye of a mammal a therapeutic amount of vasoconstrictor and a therapeutic amount of said poorly absorbing eye medicine.

12. The method of claim 15, wherein the vasoconstrictor is selected from the group consisting of alpha-1 agonist, alpha-2 agonist, alpha-3 agonist, and beta-adrenergic antagonist.

13. The method of claim 16, wherein the poorly absorbing eye medicine is tetracaine.

14. The method of claim 11, wherein the poorly absorbing eye medicine is brimonidine.